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Abstract 
Background: Multiple sclerosis (MS) and Neuromyelitis optica (NMO) 
are inflammatory and demyelinating diseases of the central nervous 
system (CNS). NK cells are supposed to play an important role in the 
pathophysiology of MS, but their role in the NMO remains unknown. 
The aim of this study was to compare the prevalence of different 
subpopulations of NK cells in the patients with MS and NMO and 
healthy individuals. 
Methods: Treatment Naive MS and NMO patients, age, and sex 
matched controls were included in this study. PBMCs were isolated 
from peripheral blood and different phenotypes of circulating NK cells 
were compared with the flow cytometry analysis. 
Results: There were no significant differences in the mean percentages 
of circulating NK cells expressing the CD56 bright molecule in patients 
with MS and NMO. However, the mean percentages of circulating NK 
cells expressing the CD56bright molecule were significantly lower in 
all patients groups, compared to controls. In addition, the mean 
percentages of circulating NK cells expressing the CD16dim molecule 
was significantly higher in the patients with MS, compared to 
controls/any other groups. The mean percentages of circulating NK 
cells expressing the CD56dim molecule were significantly higher in the 
patients with MS than the controls. There were significant differences 
in the mean percentages of circulating NK cells expressing the 
CD16bright molecule between the patients with MS, and 
NMO/controls. 
Conclusion: The results indicate that evaluation of NK cell subsets has 
an implication for the biomarker discovery and therapeutic targets in 
given diseases. 
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Introduction: 
Multiple sclerosis (MS) is an inflammatory disease that 
affects the central nervous system. Two major forms of MS 
have been reported: Relapsing-remitting (RR)-MS, which is the 
most frequent (85-90%), and primary progressive (PP)-MS. 
Indeed, most patients with MS enjoy clinically stable periods of 
variable duration (remission), although interrupted unpredictably by 
occurrence of relapse. Furthermore, most RR-MS patients later 
develop secondary progressive (SP)-MS. About 10-15% of 
patients present with insidious disease onset and steady 
progression and therefore termed (PP)-MS. It is not clear what 
factors are responsible for the different courses. Regarding the 
pathogenesis of MS, it has been shown that auto reactive T cells 
targeting myelin components play a crucial role in mediating the 
inflammatory process, particularly in the early stages of RR-MS. 
The etiology of MS remains unclear, though studies have 
demonstrated that there is a strong genetic component determining 
susceptibility to disease, the low concordance rates of monozygotic 
twins indicates a contribution of non-genetic factors to MS 
etiology. Hence, even in a genetically susceptible individual, 
additional environmental factors may be necessary for the 
pathogenic reaction against self-tissue- but the non-genetic 
trigger is still unknown. Studies using animal models suggest 
that the innate response is involved in determining whether or 
not an autoimmune reaction will occur.1 
In 1894, Devic and Gault described the sine qua non 
clinical characteristics of NMO: Optic neuritis and acute 
transverse myelitis. The patients described by Devic and Gault 
had monophasic or relapsing courses of NMO.2 Various 
antecedents or coexisting infections, vaccinations, and systemic 
autoimmune diseases have been linked to NMO but cause of 
the disease is unknown.3-5 The definition of NMO developed 
from the recognition that attacks of optic neuritis are more 
commonly unilateral than bilateral and that attacks of optic 
neuritis and myelitis usually occur sequentially rather than 
simultaneously.6 
The interval separating disease defining attacks of optic 
neuritis and myelitis can be years or decades.2,6 Ocular pain 
with loss of vision, and myelitis with severe symmetric paraplegia, 
sensory loss below the lesion, and bladder dysfunction are typical 
features of neuromyelitis optica. Cervical myelitis can extend 
into the brain stem, resulting in nausea, hiccoughs, or acute 
neurogenic respiratory failure,6-8 which is exceedingly rare in 
MS. Other symptoms typical of spinal cord demyelination that 
are seen in both NMO and MS include paroxysmal tonic 
spasms (recurrent, stereotypic painful spasms of the limbs and 
trunk that last 20-45 seconds) and Lhermitte’s symptom (spinal 
or limb dysesthesias caused by neck flexion).6,7 
The human NK cells are a heterogeneous population. While 
all of the peripheral blood human NK cells express the 
activating receptor CD161 (NKR-P1A),9 early studies 
identified two distinct populations of the human NK cells, 
based on the density of surface expression of CD56.10 
Approximately 90% of human NK cells express low density of 
CD56 (CD56dim) but have high levels of CD16, while a 
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minority (approximately 10%) of cells is CD56bright and 
CD16dim/neg. CD56 is an isoform of the human neural-cell 
adhesion molecule with unknown function on the human NK 
cells, though it might mediate interactions between NK cells 
and other cells. While the functional significance of the CD56 
molecule is unknown on NK cells, its bright or dim expression 
correlates with the expression of several other surface markers 
that confer unique functional properties to the CD56bright and 
CD56dim subsets. These NK cell subsets show important 
differences in their cytotoxic potential, capacity for cytokine 
production and responses to cytokine activation.11,12 The 
CD56bright NK cells are the primary population of NK cells that 
produce immunoregulatory cytokines, including interferon 
(IFN)-, tumor necrosis factor (TNF)-α, TNF-β, granulocyte 
monocyte-colony stimulating factor (GM-CSF), interleukin 
(IL)-10 and IL-13 following monokine stimulation.11,13  
CD56dimCD16+ NK cells constitute about 90% of total 
blood NK cells, efficiently kill target cells and secrete only low 
levels of IFN-γ. In contrast, CD56brightCD16Neg NK cells 
constitute 5-10% of total blood NK cells but are enriched in 
secondary lymphoid tissues14 and sites of autoimmune 
inflammation.15 
In contrast to the CD56dim NK cell subset, CD56bright cells 
produce a large amount of cytokines upon stimulation, but 
acquire cytolytic activity only after prolonged activation.16 
Therefore, NK cells could mediate tissue damage and regulate 
autoimmune T-cell responses through cytokine secretion and 
cytotoxicity in secondary lymphoid organs and in the inflamed 
CNS. 
Because of lack of mouse strains that are selectively 
deficient in NK cells, the study of NK cell function in vivo has 
been challenging in the past.17 MS animal models provide 
evidence for both disease-accelerating and disease-protective 
effects of NK cells.18-20 
It has been suggested that NK cells could be pathogenic by 
shaping Th1-polarized adaptive immune responses, activating 
CNS-infiltrating DCs and/or via direct recognition and lysis of 
glial and neuronal cells.20,21 However, most studies in the 
experimental autoimmune encephalomyelitis (EAE) model 
reported that NK cells protect us from autoimmune mediated 
tissue damage, presumably by editing initiator and effector cell 
populations.18, 22-24 Such apparently controversial findings 
might be explained, at least in part, by differences in timing of 
myelin immunization and NK cell activation/depletion in these 
animal models. Furthermore, NK cells could also assist T-cell 
polarization and effector function during the initiation of 
autoimmune responses against neuroantigens but might acquire 
a more suppressive function during progression of the 
established disease. Alternatively, distinct subsets of NK cells 
could mediate divergent effects on EAE initiation and 
progression. The observation by de Jager25 and others26 in 
humans, reduced frequencies of NK cells in MS patients 
together with NK cell expansion during effective immunotherapy, 
27-29 suggests that these innate lymphocytes exert beneficial 
functions. However, the mechanisms that could mediate such 
immunoregulatory NK cell functions in multiple sclerosis are 
poorly understood. 
The aim of this study is to compare the mean percentages 
of peripheral blood NK cell subsets expressing the CD16 and 
CD56 molecules in patients with MS, Devic disease (NMO), 
and healthy control subjects. 
Materials and Methods 
Twenty eight patients with RRMS, according to the McDonald 
30 criteria and EDSS(expanded disability status scale) 31 less than 
five, took part in the study. Moreover based on Wingerchuk 32 
criteria twelve seropositive NMO-IgG Devic patients and fifteen 
seronegative NMO-IgG Devic patients, according to the same 
criteria were classified into the two separated groups. Untreated 
patients, less than fifty years old and less than ten years disease 
history were included in the study. Also thirty healthy donors, 
whose age, sex and environmental conditions were matched with 
the patients, were included in the study as the control group. None 
of the controls was on any immunomodulatory or 
immunosuppressive therapy and none of them had a history of 
neurological symptoms that would indicate an acute or chronic 
neurological disease. This group did not have any acute or chronic 
diseases.  
This study was approved by the ethical committee of Isfahan 
University of Medical Sciences. Informed consent forms were 
obtained from all patients who contributed in this study. PBMCs 
were freshly isolated by density gradient centrifugation using 
Ficoll and stored in RPMI 1640 containing 50% fetal bovine serum 
(FBS) and 10% dimethyl sulfoxide (DMSO) at –80°C for later use. 
After controlling that freezing and thawing does not alter the 
viability of the cells of interest (the viability was always greater 
than 80%, and determined by trypan blue), the full series of 
samples from each patient was recovered from the freezer and 
immunofluorescence (IF) stained. 
The following antibodies were used: RPE/Cy5-conjugated 
mouse antihuman CD3 monoclonal antibody (mAb), FITC-
conjugated mouse antihuman CD16 mAb, RPE-conjugated mouse 
antihuman CD56 mAb and PE/FITC/Cy5 conjugated mouse IgG1 
Negative Controls, all from Serotec UK. 
NK cells were examined in a FACSCalibur flow cytometer 
with cell Quest software (Becton Dickinson) using three- color 
staining. Cells in Phosphate buffered saline (PBS) were incubated 
for 20 min, at 4C in the dark with specific or control antibodies. 
After staining, the cells were washed (1500 rpm, 10 min) and 
resuspended in PBS. Flow cytometer data were presented as 
percentage of positive cells calculated by gating against samples 
labeled with control isotype –matched monoclonal antibody. 
In this study, flow cytometry techniques were performed on a 
BD FACSCalibur flow cytometer (Becton Dickinson, CA, USA) 
fitted with an air-cooled 488 nm argon laser. This flow cytometer 
allowed the detection of up to three different fluorescent 
parameters. The NK cells expressing CD16 and CD56 molecules 
lower than 103 molecules on the surface of each cell were 
considered as Dim cells and the expression of these molecules on 
the surface of each cell more than 103 has been considered as 
bright cells (Figure 5). 
The fluorochromes used in this study were fluorescein 
isothiocyanate (FITC), a small organic molecule, typically 
conjugated to proteins via primary amines, Phycoerythrin (PE), 
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a phycobiliprotein-based fluorochrome, derived from algae, which 
can be conjugated to antibodies for use in immunophenotyping, 
and PE-Cy5 (PC-5). PC-5 is a tandem dye consisting of an 
indotricarbocyanine dye coupled to PE. 
Results 
The expression of CD3, CD16 and CD56 were studied on 
the peripheral blood mononuclear cells using three color-flow 
cytometry methods. Antibodies consisted of anti-CD3, anti-
CD16, anti-CD56 and isotype controls. Patients with MS 
(n=28), NMO-IgG seropositive Devic (n=12), NMO-IgG 
seronegative Devic (n=15) and controls (n=30) were included 
in this study. The age and ratio of male/female in the patients 
with MS and Devic disease were different. The results showed 
that there were no significant differences in the age means 
among the groups (P=0.112, Tables 1&2).  
One-way ANOVA test showed that the mean percentages 
of peripheral blood NK cells expressing the CD56bright 
molecule were significantly different among the groups 
(P<0.0001, Table 3 & Figure 1). Analysis with the Scheffe test 
showed that the mean percentages of peripheral blood NK cells 
expressing the CD56bright molecule was higher in the controls 
than the other groups (P<0.0001). However, there were no 
significant differences between the patients with MS, NMO+ 
and NMO- (P>0.05).  
One-way ANOVA test showed that the mean percentages 
of peripheral blood NK cells expressing the CD16dim molecule 
were significantly different between the groups (P<0.0001, 
Table 4). In this regard, analysis with the Scheffe test showed 
that the mean percentages of peripheral blood NK cells 
expressing the CD16dim molecule was higher in the patients 
with MS than the controls (P<0.0001). However, there were no 
significant differences between the other groups.  
One-way ANOVA test showed that the mean percentages 
of peripheral blood NK cells expressing the CD56dim 
moleculewere significantly different in the groups (P=0.001, 
Table 5 & Figure 2). Analysis with the Scheffe test showed that 
the mean percentages of peripheral blood NK cells expressing 
the CD56dim molecule was significantly higher in the patients 
with MS than the controls (P=0.001) and there were no 
significant differences in the other groups. 
 
Table 2. Gender distribution in all of the cases 
 
Group 
MS NMO + NMO - HC Total 
Female 18(30) 9(15) 11(18.4) 22(36.7) 60 
Male 10(40) 3(12) 4(16) 8(32) 25 
Total 28(32.9) 12(14.1) 15(17.6) 30(35.3) 85 
*The values are reported as Number (Percentage), MS: Multiple Sclerosis, NMO+: 
NMO-IgG seropositive Devic patients, NMO-: NMO-IgG seronegative Devic patients, 
HC: Healthy Controls, Chi-Square=0.812 and P.V=0.8. 
 
Table 3. Comparison of the mean percentages of peripheral 
blood NK cells expressing the CD56
bright 
molecule in the groups 
Group N Mean% SD Min Max P.V* 
MS 28 0.69 0.29 0.13 1.38 
<0.0001 
NMO+ 12 0.52 0.27 0.12 1.08 
NMO- 15 0.70 0.52 0.11 1.76 
HC 30 1.35 0.40 0.37 2.24 
*P-value calculated as one-way ANOVA test, SD: Standard Deviation, MS: Multiple 
Sclerosis, NMO+: NMO-IgG seropositive Devic patients, NMO-: NMO-IgG seronegative 
Devic patients, HC: Healthy Controls 
 
Table 4. Comparison of the mean percentages of peripheral blood 
NK cells expressing the CD16dim molecule in the groups 
Group N Mean% SD Min Max P.V* 
MS 28 25.30 15.52 2.20 61.75 
<0.0001 
NMO 
+ 
12 17.00 19.17 2.06 63.00 
NMO - 15 15.90 9.43 1.11 30.58 
HC 30 9.79 5.10 2.74 20.71 
*P-value calculated as one-way ANOVA test, SD: Standard Deviation, MS: Multiple 
Sclerosis, NMO+: NMO-IgG seropositive Devic patients, NMO-: NMO-IgG seronegative 
Devic patients, HC: Healthy Controls 
Figure 1. Comparison of the mean percentages of peripheral blood 
NK cells expressing the CD56bright molecule in the groups ± SD 
Figure 2. Comparison of the mean percentages of peripheral blood 
NK cells expressing the CD16dim molecule in the groups ± SD 
One-way ANOVA test showed that the mean percentages of 
peripheral blood NK cells expressing the CD16bright molecule 
were significantly different between the groups (P<0.0001, 
Table 6 & Figure 3). Analysis with the Scheffe test also 
showed that there were significant differences in the mean 
percentages of peripheral blood NK cells expressing the 
CD16dim molecule in patients with MS, compared to the 
Table 1. Comparison of the age means among different groups 
Group N Mean% SD Min Max P.V* 
MS 28 34.25 8.48 20.00 49.00 
0.112 
NMO + 12 28.91 8.09 14.00 43.00 
NMO - 15 32.53 8.57 21.00 48.00 
HC 30 29.53 7.99 15.00 47.00 
*P-value calculated as one-way ANOVA test, SD: Standard Deviation, MS: Multiple 
Sclerosis, NMO+: NMO-IgG seropositive Devic patients, NMO-: NMO-IgG 
seronegative Devic patients, HC: Healthy Controls 
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controls, NMO+ and NMO- groups (P<0.05). However, there 
were no significant differences between the other groups.  
Table 5. Comparison of the mean percentages of peripheral 
blood NK cells expressing the CD56dim molecule in the groups 
Group N Mean% SD Min Max P.V* 
MS 28 24.03 13.07 2.25 48.46 
0.001 
NMO + 12 18.11 14.20 4.06 46.56 
NMO - 15 21.11 13.15 3.98 44.30 
HC 30 11.51 5.65 2.39 23.73 
*P-value calculated as one-way ANOVA test, SD: Standard Deviation, MS: Multiple 
Sclerosis, NMO+: NMO-IgG seropositive Devic patients, NMO-: NMO-IgG seronegative 
Devic patients, HC: Healthy Controls 
Figure 3. Comparison of the mean percentages of peripheral blood 
NK cells expressing the CD56dim molecule in the groups ± SD  
Discussion 
This study aimed to compare the mean percentages of 
peripheral blood NK cells expressing the cell surface markers of 
CD16 and CD56 in patients with Ms, Devic disease, and healthy 
controls. The heterogeneity of idiopathic inflammatory 
demyelinating diseases of the CNS is one of the main factors that 
confound epidemiologic, genetic and therapeutic studies of MS. 
Although previously NMO was considered as a subtype of MS, 
now with combination of clinical, neuroimaging, serological, and 
pathological characteristics can be differentiated from MS (33). 
The target antigen of NMO-IgG has been recently 
identified as the mercurial-insensitive water channel protein, 
aquaporin-4 (AQP4) which is the dominant water channel 
within the CNS (34). Aquaporins (AQPs) are a family of 
widely distributed membrane-inserted water channel proteins 
providing a pathway for the osmotically-driven water transport 
through cell membranes. CNS AQPs also play a role in the 
osmoreception, K+ siphoning, CSF formation and are strongly 
implicated in the pathogenesis of cerebral edema following 
water intoxication or focal cerebral ischemia (35).  
These findings reinforce the notion that NK cells, originally 
named after their ability to mediate spontaneous cytotoxicity 
towards certain tumor cell lines, regulate the autoimmune 
responses in MS.  
Because of the lack of mouse strains that are selectively 
deficient in NK cells, the study of NK cell function in vivo has 
been challenging in the past (17). Studies from a laboratory 
revealed an unexpected mechanism of action of daclizumab in 
MS. It increases the quantity and function of immunoregulatory 
CD56bright NK cells, which downregulate adaptive T-cell 
responses.27 
Although the overall NK cell quantity or function has been 
described as diminished in patients with MS, 26 the quantity of 
immunoregulatory CD56bright NK cells has not been 
systematically studied. Studies from this laboratory first 
identified the expansion of these cells by daclizumab, based on 
their combined phenotype as the CD8αdim lymphocytes that are 
CD3−, CD4−, and CD19−.29 
Recently, an unbiased large-scale immunophenotyping 
approach identified a diminished quantity of CD8dim cells as a 
biomarker that distinguishes patients with MS and patients with 
the CIS(clinically isolated syndrome) from healthy control 
subjects.25 
Furthermore, the number of CD56bright NK cells is 
increased by several other effective immunomodulatory 
therapies in MS such as, IFN-β29 and rituximab.36 These data 
suggest that CD56bright NK cells may be relevant 
immunoregulatory cells in MS. Because type 1 interferons are 
known to enhance NK cell function 37 and conversely, because 
NK cells induce IFN-β during the viral infection,38 the 
following important question emerged: Is synergism between 
IFN-β and daclizumab required for the therapeutic efficacy in 
MS?  
Although intravenous daclizumab (1 mg/kg) administered 
every 4 weeks blocks more than 95% of CD25 on the T cells in 
the blood,29 it is unclear whether CD25 saturation is also 
achieved in tissues and whether a higher dosage of daclizumab 
may be more efficacious. In addition, it has described pilot 
biomarkers that potentially allow the early identification of 
patients who may not respond optimally to daclizumab 
monotherapy at the standard dosage. Instead, these patients 
may need a higher dosage of daclizumab or combination with 
IFN-β to achieve full therapeutic benefit. Autoimmune activity 
was regulated in MS by a delicate balance between the 
autoreactive proinflammatory immune cells and regulatory 
cells that keeps the disease-promoting cells in control.39 
Recently, NK cells have been implicated in maintaining the 
remission status of MS patients.40,41 IFN-β has been proved 
successfully in treatment of MS that aims to minimizing the 
number of relapses and slowing down the disease 
progression.29 IFN-β affects the function of the immune system 
by decreasing MHC class II expression, T-cell proliferation, 
IFN-β production and the expression of adhesion molecules.42 
Table 6. Comparison of the mean percentages of peripheral 
blood NK cells expressing the CD16bright molecule in groups 
Group N Mean% SD Min Max P.V* 
MS 28 1.34 0.83 0.00 3.12 
<0.0001 
NMO + 12 0.55 0.41 0.13 1.31 
NMO - 15 0.36 0.30 0.00 0.82 
HC 30 0.23 0.34 0.00 1.46 
*P-value calculated as one-way ANOVA test, SD: Standard Deviation, MS: Multiple 
Sclerosis, NMO+: NMO-IgG seropositive Devic patients, NMO-: NMO-IgG seronegative 
Devic patients, HC: Healthy Control. 
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A decrease in the number of NK cells has also been observed after IFN-β-therapy.29,43 
Figure 4. Flow cytometer analysis of NK cells 
 
NKT cells comprise a subgroup of NK cells expressing 
both CD56 and CD3 on their surface.44 To get more insight into 
the properties of different NK cell subtypes in the context of 
MS, a study analyzed how CD56bright and CD56dim NK cell 
populations in the peripheral blood of MS patients, respond to 
IFN-β therapy. 
The proportion of CD56bright NK-cells increases in the 
peripheral blood of MS patients after IFN-β therapy. 
Importantly, an immunoregulatory function has been suggested 
for the CD56bright NK-cells, based on their ability to secrete 
cytokines and home to lymph nodes45 and inflamed tissues.46 
Moreover, treatment of uveitis or MS with daclizumab, an IL-2 
antagonist, resulted in amelioration of the autoimmune disease 
and expansion of CD56bright regulatory NK-cells.8,27,29 
Bielekova et al. studied 22 MS patients before and after 
daclizumab therapy; before the treatment 3.3% of PBL were 
CD56bright.28 Interestingly, the patients were using IFN-β when 
the baseline sample was drawn, which might explain the rather 
high baseline percentage of the CD56bright cells when compared 
to the normal healthy controls.10 CD56bright NK-cells produce 
the anti-inflammatory cytokine IL-10 efficiently and this might 
contribute to the effective treatment associated with the 
expansion of CD56bright NK cells both after IFN-β and 
daclizumab treatment.28 CD56bright lymphocytes might also 
control the adaptive immune responses in a cell-contact-
dependent manner by the negative immunoregulation of 
activated lymphocytes.27 Recent finding of enrichment the 
CD56bright NK-cells in the secondary lymphoid tissues, as 
compared to the peripheral blood of the same individual, is 
consistent with the idea that the CD56bright NK-cells interact 
with auto reactive T cells in the secondary lymphoid organs. 
IFN-β treatment might drive enrichment of CD56bright NK-cells 
both in the secondary lymphoid tissues and in the peripheral 
blood.  
Alternatively, IFN-β might mobilize the CD56bright cells 
from the secondary lymphoid organs, which will allow their 
entry into the CNS for regulation of auto reactive T cells at the 
site of inflammation. Perhaps due to the involvement of several 
distinct subtypes of NK cells with varying roles, the experimental 
studies on the role of NK cells in MS and experimental 
autoimmune encephalomyelitis (EAE) pathogenesis have yielded 
conflicting results. Some studies suggest a protective role for 
NK cells in the autoimmune diseases. In contrast, some studies 
show that NK cells promote disease pathogenesis.47 A study 
suggest that NK cells have a role in the pathogenesis of MS 
both as the killers of oligodendrocytes21 and as the inducers of 
auto reactive T cells.48 
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Astrocytes and microglia are susceptible to NK cells injury, 
and NK cells have been detected both in the MS plaques and in 
the CSF of MS patients.22 However, another study suggests that 
NK cells play a significant role in protecting against the 
autoimmune disease, as mice deficient in NK cells develop 
more serious EAE disease.22,49 There are data to suggest that in 
the EAE model, NK-cell protection comes through killing of 
encephalitogenic T cells.50 In conclusion, the study 
demonstrates that different subtypes of NK cells are differentially 
modulated following IFN-β therapy.  
IFN-β therapy is associated with an increase in the number 
of (CD56bright) regulatory NK cells in the circulation and a 
decrease in the number of CD56dim NK cells. In addition to 
taking part in controlling autoimmune activity by interacting 
with autoreactive T cells in the secondary lymphoid tissues, 
regulatory NK-cells may also perform this function within the 
CNS.23 This can be part of the mechanism whereby IFN-β 
helps to keep MS disease activity in control. Further studies are 
needed to better understand the mechanisms controlling the 
NK-cell subtype balance during the autoimmune disease 
activity, as this might aid in developing new therapeutic 
strategies for MS. 
Regarding the mean percentages of peripheral blood NK 
cells expressing the CD16 and CD56 molecules in the patients 
with MS, Devic disease and controls, the findings of the 
present study are consistent with other findings. Both diseases 
are demyelinating inflammatory diseases, but this study 
confirms their differences concerning the immunological 
processes. 
NK cell functions in the patients with MS and other 
autoimmune diseases will potentially generate exciting insights 
into the reciprocal regulation between NK cells mediated innate 
immunity and adaptive immune responses, improve our 
capacity to target these cells as surrogate marker for the disease 
activity and treatment response and, perhaps, provide new 
prospects for the NK cell-directed therapies in MS. 
Future research on the pathogenesis of NMO would be 
facilitated by the animal models that develop the characteristic 
vascular-centric lesions in the spinal cord and optic nerves 
either spontaneously or by passive transfer of AQP4 IgG, or by 
active immunization with AQP4. 
Experiments in the EAE model have clearly demonstrated that 
endogenous conventional NK cells can suppress neuroinflammation 
and subsequent damage to CNS tissues in the course of 
autoimmune demyelinating disease. These findings are made 
even more compelling by the observation that administration of 
an immunomodulatory agent resulted in the expansion of a 
subset of NK cells in MS patients in association with clinical 
and radiological improvement. Nonetheless, a number of 
critical issues remain unresolved. 
Despite the demonstration that, under certain conditions, 
NK cells are cytotoxic towards activated T cells in vitro 
(including encephalitogenic myelin-specific T cells), the 
mechanism of action of regulatory NK cells in autoimmune 
disease in vivo remains uncertain. It is also unclear whether 
regulatory functions are a global property of NK cells or, more 
likely, possessed by a discrete subset. Such a subset might 
distinguish a unique cytokine and chemokine repertoire that 
facilitates its immunomodulatory functions. There is already a 
suggestion in the literature that regulatory NK cells preferentially 
express CX3CR1; by extrapolation, they might express a 
unique panel of adhesion molecules and chemokine receptors 
that facilitate trafficking and/or contact-dependent interactions 
necessary for their function. While CX3CL1 signaling in NK 
cells appears to be critical for their recruitment to the CNS (at 
least during EAE), it is thus far unproven that secretion of 
soluble CX3CL1 by neurons is responsible for NK cell 
migration across the blood-brain-barrier. Alternatively, it is 
possible that NK cells are altered by a CX3CL1 dependent 
event in the periphery that in turn potentiates their trafficking 
to, or retention in, the CNS and/or promotes the acquisition of 
immunoregulatory traits. 
The prospect of exploiting regulatory NK cells for therapeutic 
purposes, while intriguing, holds a number of caveats. If a cell 
surface profile of these cells is defined, one could imagine 
expanding them in vitro for autologous infusion. However, 
while a few of the studies contained an experiment in which 
purified NK cells were transferred into mice to prevent EAE, 
none showed that NK transfers could be used to suppress 
established disease. 
Furthermore, potential negative side effects of therapies 
designed to promote NK cell activity and/or increase NK cell 
frequency (such as cytokine release syndromes or cytotoxic 
injury) have not been rigorously explored. Future experimental 
therapies will more likely be based on the manipulation of 
cytokine/ chemokine pathways and cell-to-cell interactions 
involving regulatory NK cells in a manner that will boost their 
efficiency without stimulating the proinflammatory NK subsets 
to damage the healthy tissues. Before carrying out phase I of 
clinical trials, further researches are required to understand the 
biological properties of this interesting leukocyte. 
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